Technical Analysis for AVCT - Avacta Group Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical AVCT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | -6.25% | |
| 20 DMA Support | Bullish | -6.25% | |
| 50 DMA Support | Bullish | -6.25% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -6.25% | |
| Calm After Storm | Range Contraction | -6.25% | |
| Multiple of Ten Bullish | Other | -6.25% | |
| Inside Day | Range Contraction | -6.25% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Down 5% | about 13 hours ago | |
| Fell Below 50 DMA | about 16 hours ago | |
| 2x Volume Pace | about 17 hours ago | |
| 1.5x Volume Pace | about 17 hours ago | |
| Fell Below Previous Day's Low | about 18 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Sector: Healthcare
- Industry: Medical Devices
Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
Biotechnology Medicine Branches Of Biology Medical Specialties Immune System Immunology Antibodies
Biotechnology Medicine Branches Of Biology Medical Specialties Immune System Immunology Antibodies
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 215.25 |
| 52 Week Low | 12.6172 |
| Average Volume | 3,112,240 |
| 200-Day Moving Average | 105.37 |
| 50-Day Moving Average | 170.22 |
| 20-Day Moving Average | 173.93 |
| 10-Day Moving Average | 177.60 |
| Average True Range | 15.26 |
| ADX | 21.23 |
| +DI | 22.80 |
| -DI | 18.54 |
| Chandelier Exit (Long, 3 ATRs ) | 163.21 |
| Chandelier Exit (Short, 3 ATRs ) | 180.97 |
| Upper Bollinger Band | 198.93 |
| Lower Bollinger Band | 148.92 |
| Percent B (%b) | 0.32 |
| BandWidth | 28.76 |
| MACD Line | 2.76 |
| MACD Signal Line | 3.98 |
| MACD Histogram | -1.2222 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 185.85 | ||||
| Resistance 3 (R3) | 187.53 | 182.27 | 182.38 | ||
| Resistance 2 (R2) | 182.27 | 176.96 | 181.43 | 181.22 | |
| Resistance 1 (R1) | 173.63 | 173.68 | 171.00 | 171.95 | 180.06 |
| Pivot Point | 168.37 | 168.37 | 167.05 | 167.53 | 168.37 |
| Support 1 (S1) | 159.73 | 163.06 | 157.10 | 158.05 | 149.94 |
| Support 2 (S2) | 154.47 | 159.78 | 153.63 | 148.78 | |
| Support 3 (S3) | 145.83 | 154.47 | 147.63 | ||
| Support 4 (S4) | 144.15 |
